Oncological safety of fertility preservation treatment in ovarian cancer: A Spanish multicenter study
International Journal of Gynecology & Obstetrics · 2025
DOI: 10.1002/ijgo.16026 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Gynecology & Obstetrics, 2025. Verfasst von Marta Heras und 20 weiteren Autor:innen. Beteiligte Einrichtung: Gynecology Department, Hospital Universitario Santa Cristina, Madrid, Spain. Hauptthemen laut MEDLINE: Fertility Preservation, Ovarian Neoplasms. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Objective
To assess the safety of fertility‐sparing treatments for early‐stage ovarian cancer in women younger than 40 years old.
Methods
We performed a retrospective multicenter study including women aged 18–40 years diagnosed with early‐stage (FIGO I–II) ovarian cancer in 55 Spanish hospitals, from January 2010 to December 2019. Benign and borderline tumors were excluded, as well as advanced stages (FIGO III–IV). All perioperative characteristics and follow‐up data were collected and analyzed. Standard staging surgery (SSS) was compared with fertility‐sparing surgery (FSS) in terms of oncological outcomes.
Results
In all, 366 women were included; 327 (89.3%) were stage I. Among all patients, 216 (59%) underwent SSS and 150 (41%) FSS. Up to 208 (56.8%) patients did not have children, but only 12 (3.2%) had oocyte preservation before treatment. Patients in the FSS group compared with the SSS group showed a non‐significant difference in recurrences (8% vs. 9.3%, respectively; P < 0.711) and deaths (1.3% vs. 4.8%, respectively; P = 0.211) during the follow‐up. No significant differences were found between epithelial and non‐epithelial ovarian cancer both in recurrences (7.1% vs. 8.8%, respectively; P = 0.771) and in deaths (1.4% vs. 1.3%, respectively; P = 1) among patients who underwent FSS.
Conclusion
FSS seems a safe option for treatment of early‐stage ovarian cancer in patients who want to preserve fertility, either for epithelial and non‐epithelial histology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gynecology Department, Hospital Universitario Santa Cristina, Madrid, Spain.
- Gynecology Department, Hospital Universitario Virgen de la Macarena, Seville, Spain.
- Gynecology Department, Hospital Universitario Insular Materno Infantil de Canarias, Gran Canaria, Spain.
- Gynecology Department, IMED Hospitales, Valencia, Spain.
- Gynecology Department, Hospital Universitario Bellvitge, Barcelona, Spain.
- Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain.
ORCID-Profile: Marta Heras, Mikel Gorostidi
Zitieren
APA
Heras, M., Azcona, L., Arencibia, O., Minig, L., Marti, L., Hernandez, A., Lekuona, A., Niguez, I., Gil-Ibañez, B., Diaz-Feijoo, B., Ribot, L., Cabezas, M. N., Lamarca, M., Bellon, M., Alkourdi, A., Cardenas, L., Boldo, A., Amengual, J., Gorostidi, M., …, & YOC‐Care Collaborative Group (2025). Oncological safety of fertility preservation treatment in ovarian cancer: A Spanish multicenter study. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.16026
Vancouver
Heras M, Azcona L, Arencibia O, Minig L, Marti L, Hernandez A, et al. Oncological safety of fertility preservation treatment in ovarian cancer: A Spanish multicenter study. International Journal of Gynecology & Obstetrics. 2025. doi:10.1002/ijgo.16026
BibTeX
@article{Heras2025,
author = {Heras, Marta and Azcona, Leticia and Arencibia, Octavio and Minig, Lucas and Marti, Lola and Hernandez, Alicia and Lekuona, Arantxa and Niguez, Isabel and Gil-Ibañez, Blanca and Diaz-Feijoo, Berta and Ribot, Laia and Cabezas, Maria Nieves and Lamarca, Marta and Bellon, Monica and Alkourdi, Amira and Cardenas, Laura and Boldo, Ana and Amengual, Joana and Gorostidi, Mikel and Zapardiel, Ignacio and YOC‐Care Collaborative Group, YOC‐Care Collaborative Group},
title = {Oncological safety of fertility preservation treatment in ovarian cancer: A Spanish multicenter study},
journal = {International Journal of Gynecology & Obstetrics},
year = {2025},
doi = {10.1002/ijgo.16026}
}
EUVIMED